Prognostic Molecular Mammary Tumour Panel
The Prognostic Molecular Mammary Tumor Panel is a comprehensive immunohistochemical panel developed to assess the biological behavior of mammary tumors in veterinary patients. This panel includes nine antibodies: Her-2, estrogen receptor (ER), progesterone receptor (PR), cytokeratin 5/6 (CK5/6), epidermal growth factor receptor (EGFR), Ki-67, p63, E-cadherin, and P-cadherin. By analyzing these markers, the panel provides valuable insights into the tumor’s molecular phenotype,predicting tumor behavior, aggressiveness, and potential therapeutic responses.
Test name
Prognostic Molecular Mammary Tumour Panel
Test Code
1015
Section
Cancer Diagnostics
Species
Canine
Specimen
One of the following: fixed tissue in 10% formalin, paraffin embedded tissue, or 3 unstained formalin-fixed tissue sections on positively charged slides. Slide preparation using submitted tissue will incur a ₹1500 charge.
Collection Container
Tissue: Samples must be submitted in sealed, leak-proof, wide-mouth plastic containers. Glass containers are not acceptable and will incur an additional processing fee
Slides: Samples should be submitted in designated slide containers.
Turnaround time
14-21 days
Packing Instructions
Label each sample with the animal’s name and a unique identifier, using a permanent marker or a secure adhesive label. Ensure the submittal form is completed with the animal’s information and relevant medical history.
References
- Gama, A., Alves, A., & Schmitt, F. “Identification of Molecular Phenotypes in Canine Mammary Carcinomas with Clinical Implications.” Veterinary Pathology, 2020.
- Millanta, F., et al. “Prognostic Relevance of HER2 and Hormone Receptors in Canine Mammary Tumors.” Journal of Veterinary Science, 2021.
- Peña, L., et al. “Application of Molecular Markers in Diagnosing and Predicting Prognosis of Mammary Carcinomas in Veterinary Medicine.” Journal of Comparative Pathology, 2022.
